# A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

> **NCT07051486** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Recurrent or Metastatic Cervical Cancer

## Interventions

- **DRUG:** SHR-A1811 Injection

## Key facts

- **NCT ID:** NCT07051486
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-11
- **Primary completion:** 2026-02
- **Final completion:** 2026-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07051486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07051486, "A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07051486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*